CHEMORES is an EU funded research collaboration involving clinicians and scientists at 19 universities, organizations for cancer research and research-oriented biotechnology companies in eight European countries. The purpose of the project is to improve cancer treatment by obtaining increased knowledge on mechanisms of chemotherapy resistance.

Lung cancerCancer represents one of the most serious health problems in Europe. It is estimated that the two diseases that are studied in CHEMORES, lung cancer and melanoma, caused over 350,000 deaths in Europe in 2002. An important contributing factor in cancer mortality is the fact that the most common types of cancer do not respond well to systemic chemotherapy in the advanced stages. Increased understanding of the underlying processes will contribute to the development of predictors of both therapy response and toxicity, and in the end more efficient and personalised therapy.

 

 

 

 

 

NEWS

 

THIRD ANNUAL REPORT

The third annual report for the CHEMORES project was sent to the EC in March 2010. Click here for a summary of the report.

WORKSHOP ON CHEMORESISTANCE

An open workshop entitled "CHEMORESISTANCE: a major treatment failure in oncology" was held in Milan, January 21, 2009. Please see Calendar for more information and links to presentations.

MEETINGS

The third annual CHEMORES meeting was held in Madrid, January 2010. Scientific progress and administrative issues were discussed. The next meeting is planned to be held in Manchester, January 2011.


The information given here reflects the author’s view only. The European Community is not liable for any use that may be made of the information.
 
6th

ProjectCoordinator (members only)

Page updated by Chemores June 29, 2010
Print info: http://chemores.ki.se /index.html - Saturday, 04-Sep-2010 01:48:33 CEST
Producerad av Mediabyrån